MNG772
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.398
- HYPOXIA+0.273
- KRAS_SIGNALING_DN+0.238
- OXIDATIVE_PHOSPHORYLATION+0.237
- HEME_METABOLISM+0.228
- ANDROGEN_RESPONSE+0.206
- MYOGENESIS+0.199
- BILE_ACID_METABOLISM+0.186
- ADIPOGENESIS+0.184
- P53_PATHWAY+0.175
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.544
- INTERFERON_GAMMA_RESPONSE-0.479
- ALLOGRAFT_REJECTION-0.362
- E2F_TARGETS-0.362
- IL6_JAK_STAT3_SIGNALING-0.280
- G2M_CHECKPOINT-0.251
- MYC_TARGETS_V1-0.229
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.227
- UNFOLDED_PROTEIN_RESPONSE-0.203
- DNA_REPAIR-0.195
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG682 | — | — | 0.769 |
| 2 | SRR8613741 | — | F | 0.743 |
| 3 | SRR816770 | GTEX | — | 0.734 |
| 4 | TCGA-2F-A9KQ-01A-11R-A38B-07 | — | — | 0.704 |
| 5 | TCGA-CV-6935-01A-11R-1915-07 | — | — | 0.702 |
| 6 | MNG384 | — | — | 0.699 |
| 7 | SRR817715 | GTEX | — | 0.699 |
| 8 | MNG965 | — | — | 0.687 |
| 9 | aMVAC.P_003_TURBT_S220 | — | — | 0.681 |
| 10 | SRR8613710 | — | F | 0.680 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.398 | Remibrutinib | — uncovered |
| HYPOXIA | 0.273 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.238 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.237 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.228 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.206 | Inavolisib | — uncovered |
| MYOGENESIS | 0.199 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.186 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.184 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.175 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.174 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.169 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.168 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.167 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.147 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.136 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.133 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.110 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.094 | Inavolisib | — uncovered |